255 related articles for article (PubMed ID: 26643326)
1. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Zhang X; Setze C; Rodrigues L; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2016 Feb; 60(2):1106-13. PubMed ID: 26643326
[TBL] [Abstract][Full Text] [Related]
2. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
4. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
5. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Krishnan P; Tripathi R; Schnell G; Reisch T; Beyer J; Irvin M; Xie W; Larsen L; Cohen D; Podsadecki T; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2015 Sep; 59(9):5445-54. PubMed ID: 26100711
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
7. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Smith MA; Lim A
Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
9. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Lu L; Dekhtyar T; Hall C; Vilchez RA; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2015 Nov; 59(11):6807-15. PubMed ID: 26282418
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
12. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
Miyasaka A; Yoshida Y; Yoshida T; Murakami A; Abe K; Ohuchi K; Kawakami T; Watanabe D; Hoshino T; Sawara K; Takikawa Y
Intern Med; 2018 Oct; 57(19):2807-2812. PubMed ID: 29780135
[TBL] [Abstract][Full Text] [Related]
13. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
14. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
15. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
16. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.
Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I
J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886
[TBL] [Abstract][Full Text] [Related]
17. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Deeks ED
Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
[TBL] [Abstract][Full Text] [Related]
18. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
[TBL] [Abstract][Full Text] [Related]
20. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.
Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Dekhtyar T; Irvin M; Hall C; Yu Y; Mobashery N; Redman R; Pilot-Matias T; Collins C
J Viral Hepat; 2018 Sep; 25(9):1078-1088. PubMed ID: 29624809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
